Silencing insulin‑like growth factor‑1 receptor expression inhibits gastric cancer cell proliferation and invasion

Ge,Jie; Chen,Zihua; Huang,Jin; Yuan,Weijie; Den,Zhenghao; Chen,Zhikang

doi:10.3892/mmr.2014.2746

Silencing insulin‑like growth factor‑1 receptor expression inhibits gastric cancer cell proliferation and invasion

Authors:
- Jie Ge
- Zihua Chen
- Jin Huang
- Weijie Yuan
- Zhenghao Den
- Zhikang Chen
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: October 22, 2014 https://doi.org/10.3892/mmr.2014.2746
Pages: 633-638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The oncoprotein insulin‑like growth factor‑1 receptor (IGF‑1R) has previously been shown to promote tumorigenesis. Overexpression of IGF‑1R is considered to be a critical prerequisite for malignant transformation in numerous human cancers. Therefore, targeting IGF‑1R for cancer therapy has gained a lot of interest. In the present study, an RNA interference (RNAi)‑mediated IGF‑1R gene silencing approach was conducted in BGC823 gastric cancer cells. The tumorigenic and malignant properties of the cells were assessed, in response to reduced IGF‑1R expression. Notably, IGF‑1R depletion not only inhibited gastric cancer cell growth, resulted in G1 cell cycle arrest and consequently led to apoptosis, but also suppressed cancer cell motility and invasion. The findings of the present study are the first, to the best of our knowledge, to suggest that RNAi‑based IGF‑1R silencing may be a potential and promising therapeutic strategy for gastric cancer treatment.

View Figures

View References

1	Salmon WD Jr and Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 49:825–836. 1957.
2	Maki RG: Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 28:4985–4995. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sell C, Rubini M, Rubin R, et al: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 90:11217–11221. 1993. View Article : Google Scholar
4	Werner H: Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene. 31:2703–2714. 2012. View Article : Google Scholar : PubMed/NCBI
5	Seccareccia E and Brodt P: The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res. 22:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
6	Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
7	Deng Y, Wang CC, Choi KW, et al: Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 538:217–227. 2014. View Article : Google Scholar : PubMed/NCBI
8	Castel SE and Martienssen RA: RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Genet. 14:100–112. 2013. View Article : Google Scholar : PubMed/NCBI
9	Guo J, Evans JC and O’Driscoll CM: Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer? Trends Mol Med. 19:250–261. 2013. View Article : Google Scholar : PubMed/NCBI
10	Levine AJ and Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 9:749–758. 2009.PubMed/NCBI
11	Lane DP, Cheok CF and Lain S: p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010.PubMed/NCBI
12	Oren M and Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2:a0011072010. View Article : Google Scholar : PubMed/NCBI
13	Ge J, Chen Z, Wu S, et al: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion. 80:148–158. 2009. View Article : Google Scholar
14	Werner H, Karnieli E, Rauscher FJ and LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA. 93:8318–8323. 1996. View Article : Google Scholar : PubMed/NCBI
15	Nahor I, Abramovitch S, Engeland K and Werner H: The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res. 15:388–396. 2005. View Article : Google Scholar : PubMed/NCBI
16	Maor S, Yosepovich A, Papa MZ, et al: Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett. 257:236–243. 2007. View Article : Google Scholar : PubMed/NCBI
17	Maor SB, Abramovitch S, Erdos MR, Brody LC and Werner H: BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab. 69:130–136. 2000. View Article : Google Scholar : PubMed/NCBI
18	Yuen JS, Cockman ME, Sullivan M, et al: The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene. 26:6499–6508. 2007. View Article : Google Scholar : PubMed/NCBI
19	Werner H, Re GG, Drummond IA, et al: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA. 90:5828–5832. 1993. View Article : Google Scholar : PubMed/NCBI
20	Werner H, Shen-Orr Z, Rauscher FJ III, et al: Inhibition of cellular proliferation by the Wilms’ tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol. 15:3516–3522. 1995.
21	Niu J, Xu Z, Li XN and Han Z: siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53. Cell Biol Int. 31:156–164. 2007. View Article : Google Scholar : PubMed/NCBI
22	Min Y, Adachi Y, Yamamoto H, et al: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 54:591–600. 2005. View Article : Google Scholar
23	Tian D and Kreeger PK: Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy. BMC Syst Biol. 8:982014. View Article : Google Scholar
24	Denley A, Cosgrove LJ, Booker GW, Wallace JC and Forbes BE: Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 16:421–439. 2005. View Article : Google Scholar : PubMed/NCBI
25	Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI